Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
Verastem presented new RAMP 201 analyses at IGCS 2026 showing avutometinib plus defactinib activity in KRAS wild-type recurrent low-grade serous ovarian cancer, with ORRs of 22% in NRAS/BRAF-mutated and 18% in KRAS/NRAS/BRAF triple wild-type tumors. An external control arm analysis versus conventional care showed weighted ORR of 38.7% versus 0% and median PFS of 22.1 versus 6.5 months in KRAS-mutated disease, with statistically significant PFS improvements in both subgroups.
Key figures
- Drug Name
- avutometinib plus defactinib (AVMAPKI FAKZYNJA CO-PACK)
- Phase Of Trial
- Phase 2
- RAMP201 J ORR
- 44%
- Orr triple wild type
- 18%
- Weighted ORR KRAS mutated
- 38.7% vs 0% conventional care
- Weighted ORR KRAS wild type
- 22.7% vs 7.9%
- M PFS triple wild type months
- 13
- RAMP201 J disease control rate
- 94%
- Orr kras wt NRAS BRAF mutated
- 22%
- Weighted m PFS KRAS mutated months
- 22.1 vs 6.5
- Weighted m PFS KRAS wild type months
- 11.3 vs 7.7
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.